anti-CD19 CAR-T therapy + mosunetuzumab + polatuzumab vedotin

This combination regimen is a chemoimmunotherapy approach being evaluated for the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). The therapy involves the administration of an FDA-approved anti-CD19 chimeric antigen receptor (CAR) T-cell therapy followed by a consolidation phase using mosunetuzumab and polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b that delivers the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) directly to B cells. Mosunetuzumab is a bispecific monoclonal antibody that targets both CD20 on B cells and CD3 on T cells, facilitating T-cell mediated killing of malignant B cells. The anti-CD19 CAR-T therapy provides a direct cellular immune response against CD19-expressing lymphoma cells. This multi-targeted approach aims to improve durable response rates in patients who have failed prior lines of therapy.

Brand names

PolivyLunsumio

Other names

CAR-T with Mosunetuzumab and Polatuzumab for R/R Aggressive NHL